Personalized mRNA Vaccine Cuts Melanoma Recurrence by Over 40 Percent
⏮ BeforePatients at risk of melanoma recurrence had limited options to lower that risk with a personalized vaccine.
✅ NowIn a Phase 3 trial, the personalized mRNA vaccine reduced recurrence risk by over 40 percent.
In short
- The vaccine is tailored to each patient's own tumor.
- Results come from a Phase 3 trial, the last stage before approval.
- The reported reduction in recurrence risk is over 40 percent.
Why the Good News Desk likes this one
Recurrence is one of the main fears for people who have had melanoma removed. This trial adds to evidence that mRNA vaccines can be used against cancer, not only against infections. The source reports the result from a Phase 3 trial, so wider use depends on further regulatory review.
Advertisement
From WIRED
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
Ask this story
📜 The story so far
- 22 Oct 2026 Personalized Cancer Vaccine Cuts Melanoma Recurrence Risk by 42 Percent Where it started.
- 23 Oct 2026 Moderna mRNA vaccine almost halves risk of melanoma returning The same Moderna melanoma vaccine trial result is now described as almost halving recurrence risk, a rephrasing of the earlier 42 percent figure rather than a new development.
- 23 Oct 2026 Personalized mRNA vaccine cuts melanoma recurrence risk in late-stage trial The same personalized mRNA melanoma vaccine's 42% recurrence-risk reduction is now reported from a late-stage trial, with the risk figure restated as death too.
- 23 Oct 2026 Moderna and Merck personalised melanoma vaccine cuts recurrence in trial The same Moderna and Merck melanoma vaccine trial is reported again, now describing delayed return and spread of the cancer in the trial data.
- 23 Oct 2026 Personalised mRNA cancer vaccine cuts melanoma return risk by 42% The same 42% melanoma result is now reported with more detail, adding that it is a Phase III trial of the Keytruda-combined vaccine.
- 24 Oct 2026 Personalized mRNA Vaccine Cuts Melanoma Recurrence by Over 40 Percent The same personalized mRNA melanoma vaccine's Phase 3 trial result is now reported as cutting recurrence risk by over 40 percent.
More like this
Advertisement